PLA2G2A and breast carcinoma: In order to enable analyses of drug release profiles with living cells, we devised a system with luciferin remote-loaded sPLA2-sensitive liposomes and MCF-7 breast cancer cells engineered to produce firefly luciferase (luc2 gene) and sPLA2 enzymes, so that drug release can be monitored by emergence of luminescence.